Human Stem Cell-Derived Retinal Pigment Epithelial Cells as a Model for Drug Screening and Pre-Clinical Assays Compared to ARPE-19 Cell Line

• Published in: International journal of stem cells 2021-02, Vol.14 (1), p.74-84
• Main Authors: Oliveira, Carolina Reis, Paiva, Mayara Rodrigues Brandão de, Ribeiro, Marcela Coelho Silva, Andrade, Gracielle Ferreira, Carvalho, Juliana Lott, Gomes, Dawidson Assis, Nehemy, Márcio, Fialho, Sílvia Ligório, Silva-Cunha, Armando, Góes, Alfredo Miranda de
• Format: Article
• Language: English
• Subjects: Original
• ISSN: 2005-3606; 2005-5447
• DOI: 10.15283/ijsc20094

Eye diseases have a high socioeconomic impact on society and may be one of the fields in which most stem cell-related scientific accomplishments have been achieved recently. In this context, human Pluripotent Stem Cell (hPSC) technology arises as an important tool to produce and study human Embryonic Stem cell derived-Retinal Pigmented Epithelial Cells (hES-RPE) for several applications, such as cell therapy, disease modeling, and drug screening. The use of this technology in pre-clinical phases attends to the overall population desire for animal-free product development. Here, we aimed to compare hES-RPE cells with ARPE-19, one of the most commonly used retinal pigmented epithelial immortalized cell lines. Functional, cellular and molecular data obtained suggest that hES-RPE cells more closely resembles native RPEs compared to ARPE-19. Furthermore, hES-RPE revealed an interesting robustness when cultured on human Bruch's membrane explants and after exposure to Cyclosporine (CSA), Sirolimus (SRL), Tacrolimus (TAC), Leflunomide (LEF) and Teriflunomide (TER). On these conditions, hES-RPE cells were able to survive at higher drug concentrations, while ARPE-19 cell line was more susceptible to cell death. Therefore, hES-RPEs seem to have the ability to incur a broader range of RPE functions than ARPE-19 and should be more thoroughly explored for drug screening.